Alfasigma to buy Intercept Pharmaceuticals for $794m
Alfasigma has signed a definitive agreement for the acquisition of Intercept Pharmaceuticals in an all-cash deal valued at $794m.
Alfasigma has signed a definitive agreement for the acquisition of Intercept Pharmaceuticals in an all-cash deal valued at $794m.
What's Your Reaction?
